AstraZeneca Results Presentation Deck
Analysis: core operating profit and net debt
Increasing operating leverage and cash flow progress
$m
2,250
2,000
1,750
1,500
1,250
1,000
750
500
250
T
Q3 2017
Q4 2017
Core operating profit
Sources of profit continued to progress
Q1 2018
Q2 2018
Return Return
to
to
sales
revenue
growth growth
Residual Collaboration revenue (CR) Core O01
Absolute values at actual exchange rates.
22
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
$bn
11.9
Net debt end 2019
8.3
EBITDA
Net debt broadly stable reflecting
continued improvement in EBITDA
0.4
Working capital, short-term provisions
2.9
Other operating cash, disposals
1.0
Capex
1.2
1. Earnings before interest, tax, depreciation and amortisation; last four quarters.
AstraZeneca credit ratings:
Contingent and intangible assets
and non-current asset investments
Net debt: $12,110m
EBITDA¹: $8,311m
3.6
Dividends
0.3
Other
12.1
Net debt end 2020
Moody's: short-term rating P-2, long-term rating A3, outlook negative.
Standard & Poor's: short-term rating A-2, long-term rating BBB+, outlook positive.
BView entire presentation